However, this participant had a slower dose titration due to their heart failure, so took longer to reach the maximum dose
Wegovy or Zepbound should not be used by people with a personal or family history of medullary thyroid carcinoma, MEN 2, or a prior serious hypersensitivity reaction to the specific medication or its ingredients
2025 Cliawaived, Inc
[DOI] [PMC free article] [PubMed] [Google Scholar] 122.Neuen B.L., Fletcher R.A., Anker S.D., Bhatt D.L., Butler J., Cherney D.Z.I., Docherty K.F., Inzucchi S.E., Jardine M.J., Mahaffey K.W., et al
Who Might Benefit Zepbound may be the strongest option for Hashimoto's patients who: Have a BMI of 30 or greater, or 27 or greater with at least one weight-related condition Haven't achieved meaningful weight loss with other medications or lifestyle interventions Have significant insulin resistance or prediabetes alongside their Hashimoto's Carry improved inflammatory markers (hsCRP above 3.0 mg/L) Want the maximum weight loss potential currently available in a single medication Don't have a history of medullary thyroid cancer or MEN2 Zepbound is FDA-approved for chronic weight management, so Hashimoto's patients who meet the BMI criteria have a recognized pathway to treatment
